NewsRx

Search our medical news database

Monoclonal Antibody

CNTO 95 blocks alpha(v) integrins to suppress tumors in mice

Published in Cancer Weekly, July 20th, 2004

CNTO 95 blocks alpha(v) integrins to suppress tumors in mice.

According to a study from the United States, "integrins of the alpha(v) family, such as alpha(v)beta(3) and alpha(v)beta(5), are implicated in tumor-induced angiogenesis; but their role in tumor growth has not been fully explored. CNTO 95 is a fully human antibody that recognizes the alpha(v) family of integrins and is likely to be less immunogenic in humans compared to chimeric or humanized antibodies."

"CNTO 95 bound to purified alpha(v)beta(3) and alpha(v)beta(5) with a K-d of approximately 200 pM and to alpha(v) integrin-expressing human cells with a K-d of 1-24 nM. In vitro, CNTO 95...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook